Afleveringen
-
Guest: Ryan Maves, MD
Guest: Susan Corbridge, PhD, APRN, ACNP-BC, FAANP, FCCP, FAAN
Although there have been several advances in vaccine technology and safety the past few years, the prevalence of vaccine hesitancy among patients is increasing. Since vaccine hesitancy heightens the burden of potentially life-threatening viruses like RSV and influenza, Dr. Ryan Maves speaks with Dr. Susan Corbridge about why patients might be reluctant to get vaccinated and how we can use the First 5 Minutes approach to provide individualized counseling on the importance of vaccines. Dr. Maves is a Professor of Medicine and Anesthesiology in the Sections of Infectious Diseases and Critical Care Medicine at the Wake Forest University School of Medicine, and Dr. Corbridge is a Professor Emerita at the University of Illinois at Chicago College of Nursing.
This episode is supported by an educational grant from Moderna.
-
Host: Angela Birdwell, DO, MA, FCCP
Guest: Antonio Anzueto, MD
Guest: Susan Corbridge, PhD, APRN, ACNP-BC, FAANP, FCCP, FAAN
Although the prevalence of chronic obstructive pulmonary disease (COPD) has decreased in adults aged 18 to 44, it remains elevated in certain patient groups, like women, adults over 65, smokers, and those living in rural areas. This prevalence emphasizes the importance of a patient-centered approach, which is why Dr. Angela Birdwell speaks with Drs. Antonio Anzueto and Susan Corbridge about how open conversations and the First 5 Minutes concept can help personalize the care of COPD patients and lead to better outcomes. Dr. Anzueto is a Professor of Medicine at the South Texas Veterans Health Care System and UT Health San Antonio, and Dr. Corbridge is the Chief Essentials Program Officer at the American Association of Colleges of Nursing and a Professor Emerita at the University of Illinois at Chicago College of Nursing.
This non-CME education is brought to you by CHEST, and this program is supported by Regeneron Pharmaceuticals, Inc. and Sanofi.
-
Zijn er afleveringen die ontbreken?
-
Host: Farrukh Abbas, MD
Guest: Megan Conroy, MD, MA(Ed), FCCP
Listen in as Farrukh Abbas, MD, FCCP, and Megan Conroy, MD, MAEd, FCCP, discuss the role of the care team in COPD diagnosis, recent changes in classifications and updates to the GOLD guidelines, how triple-inhaler therapies and biologics can be used to treat patients with COPD, and more.
Since the time of this recording, the FDA has recently approved dupilumab as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) with type 2 inflammation.
-
Host: Tom Corbridge, MD, FCCP
Guest: De De Gardner, DrPH, RRT, RRT-NPS, FAARC, FCCP
Guest: Diego Maselli, MD
Guest: Praveen Akuthota, MD
As we continue to learn more about the underlying inflammatory pathways in asthma, we now have more novel tools and treatments to help us achieve control, remission, and better outcomes for our patients. But in order to achieve those goals, we must first detect severe asthma early enough to take full advantage of the latest advancements. Learn more about the importance of early detection and intervention in severe asthma care through the lens of a real-world patient case with Drs. Tom Corbridge, De De Gardner, Diego Maselli, and Praveen Akuthota.This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
-
Host: Ashwin Basavaraj, MD
Guest: Christopher Lippincott, MD, MPH
Bronchiectasis is a complex syndrome that can lead to an interconnected cascade of airway dysfunction and inflammation. How has our understanding of this syndrome evolved with Cole’s vicious cycle hypothesis? Dr. Ashwin Basavaraj and Dr. Christopher Lippincott take a closer look at this hypothesis and the clinical mechanisms behind bronchiectasis.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
-
Guest: Ashwin Basavaraj, MD
Host: Christopher Lippincott, MD, MPH
From airway clearance techniques and mucoactive therapy—what can clinicians do to manage bronchiectasis exacerbations? To answer this question, Dr. Christopher Lippincott and Dr. Ashwin Basavaraj explore the mechanisms that lead to bronchiectasis and share strategies to manage exacerbations.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
-
Host: Stephanie Christenson, MD
Guest: Ron Balkissoon, MD, MSc, DIH, FRCPC
What do we need to know about the pathophysiology and burden of COPD exacerbations? To better understand this—and the factors that may put our patients at risk—Dr. Stephanie Christenson from the University of California San Francisco and Dr. Ron Balkissoon from National Jewish Health share insights on COPD exacerbations.
This is a non-promotional, non-CME disease state educational program brought to you by CHEST in collaboration with and sponsored by GSK.
-
Host: Stephanie Christenson, MD
Guest: Ron Balkissoon, MD, MSc, DIH, FRCPC
What is a COPD exacerbation, and what puts our patients at risk of them? Drs. Stephanie Christenson and Ron Balkissoon discuss these risks and the burden of COPD exacerbations on our patients.
This is a non-promotional, non-CME disease state educational program brought to you by CHEST in collaboration with and sponsored by GSK.
-
Host: Randy Young, MD
Guest: Tufik Assad, MD, MSCI
What are the factors that make diagnosing pneumonia challenging, and how might emerging testing modalities improve that? To answer this question, Dr. Randy Young and Dr. Tufik Assad from the Williamson Medical Center in Franklin, Tennessee dive into the etiology, diagnostic challenges, and current trends in pneumonia diagnostics.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by bioMèrieux.
-
Host: Randy Young, MD
Guest: Daniel Jay Feinstein, MD, FACP, MS, ACRP-PI
Diagnosing pneumonia can be challenging, but the CAP guidelines offer recommendations to improve the detection of this infection. To find out more about the recommendations, Dr. Randy Young and Dr. Daniel Feinstein, a Physician Executive at Novant Health, dive into testing for pneumonia.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by bioMèrieux.
-
Host: Frank C. Sciurba, MD, FCCP
Guest: Emily L. Yee, MD
What do we need to know about using endobronchial valves in patients with severe COPD and emphysema? Drs. Frank Sciurba and Emily Yee explore the impact of these valves on patients.
This educational podcast is produced in partnership with the American College of CHEST Physicians and sponsored by Pulmonx Corporation, the manufacturer of Zephyr. Click here to find additional educational resources for clinicians and patients.
-
Host: Doreen Addrizzo-Harris, MD
Guest: Ashwin Basavaraj, MD
From evaluating diagnostic criteria to nonpharmacologic therapy, what do the NTM guidelines recommend when it comes to the treatment of MAC lung disease? Drs. Doreen Addrizzo-Harris and Ashwin Basavaraj from NYU Grossman School of Medicine will dive into the practical application of the NTM guidelines.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
-
Host: Ashwin Basavaraj, MD
Nontuberculous mycobacteria (NTM) and bronchiectasis are challenging diseases that require a multidisciplinary approach to treat. Dr. Ashwin Basavaraj sits down with his patient, Mary, to learn more about these obstacles and discuss how we can find the right care team.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
-
Host: David Schulman, MD, MPH, FCCP
Guest: Andrew H. Limper, MD
Guest: Timothy A. Hernandez, MD
There are many barriers to reaching a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). To learn more about these obstacles—and how we can overcome them—Dr. David Schulman from the American College of Chest Physicians joins Dr. Tim Hernandez from the University of Texas Health Sciences Center and Dr. Andrew Limper from the Mayo Clinic to discuss the diagnosis of IPF.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
Click here to receive updates on Bridging Specialties™ and how you can be involved.
-
Host: Peter Howarth BSc, (Hons), MBBS, DM, FRCP
Guest: Kathleen M. Buchheit, MD
Guest: Philippe Gevaert, MD, PhD
Do cytokines play a role in chronic rhinosinusitis? Dr. Peter Howarth is joined by Dr. Katie Buchheit, an Associate Professor of Medicine at Harvard Medical School, and Professor Philippe Gevaert, an ENT specialist at the Department of Otorhinolaryngology at Ghent University and the Upper Airway Research Laboratory, to explore the role of inflammatory mediators in the progression of chronic rhinosinusitis with nasal polyps.
This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.
-
Host: Peter Howarth BSc, (Hons), MBBS, DM, FRCP
Guest: Ian Pavord, MA, DM, FRCP, FERS, FMedSci
Guest: Geoffrey Chupp, MD
Type 2 inflammation can be challenging to identify. What should we be looking for in our patients with severe asthma and COPD? Joining Dr. Peter Howarth to discuss identifying this type of inflammation are Dr. Geoffrey Chupp from the Yale School of Medicine and Dr. Ian Pavord from the University of Oxford.
This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.
-
Host: Muhammad Adrish MD, MBA, FCCP, FCCM
Guest: Navitha Ramesh, MD, FCCP
Inhalers are one of the most common methods of delivery for the treatment of COPD, but is it the best option for all of our patients? Associate Professor of Pulmonary Critical Care at Baylor College of Medicine, Dr. Muhammad Adrish, reviews LAMA use for COPD patients with Dr. Navitha Ramesh, Assistant Professor at Drexel University College of Medicine.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
-
Host: Megan Conroy, MD, MA(Ed), FCCP
Guest: Farrukh Abbas, MD
On average, more than two-thirds of patients with chronic obstructive pulmonary disease (COPD) make at least one error in using an inhaler device. Fortunately, nebulized long-acting muscarinic antagonists (LAMAs) can help our patients overcome this common challenge in COPD care. That’s why Drs. Megan Conroy and Farrukh Abbas come together to talk about the GOLD treatment guidelines, strategies for reducing patient hesitancy regarding nebulized LAMAs, and more.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
-
Host: Tom Corbridge, MD, FCCP
Guest: Michael E. Wechsler, MD, MMSc
Severe asthma is an uncontrolled disease that can be difficult to diagnose. To help us overcome this obstacle, Dr. Tom Corbridge joins Dr. Michael Wechsler from National Jewish Health in Denver to discuss the challenges we face while trying to diagnose severe asthma.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
-
Guest: Jared Nathan Silver, MD, PhD
Guest: Praveen Akuthota, MD
Eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndromes are often mistaken for each other. How can we better distinguish these diseases? Dr. Jared Silver discusses how to diagnose these diseases with Dr. Praveen Akuthota, a pulmonologist from U.C. San Diego Medical Center in California.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
- Laat meer zien
